Last reviewed · How we verify

Seizures associated with CDKL5 deficiency disorders — Treatment Landscape & Competitive Intelligence

Seizures associated with CDKL5 deficiency disorders (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Seizures associated with CDKL5 deficiency disorders, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ztalmy GANAXOLONE Marinus Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] GABA A receptor alpha-2/beta-1/gamma-2 2022-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Marinus · 1 drug in Seizures associated with CDKL5 deficiency disorders

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Seizures associated with CDKL5 deficiency disorders:

Cite this brief

Drug Landscape (2026). Seizures associated with CDKL5 deficiency disorders — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/seizures-associated-with-cdkl5-deficiency-disorders. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing